Commercial Support

The Conference on Retroviruses and Opportunistic Infections (CROI) is largely supported by the registration fees of participants. In addition, the IAS–USA seeks grant support from ineligible companies, particularly from companies with competing products, in the interest of objective, balanced, and scientifically rigorous activities. The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” These companies have no input in or control over the selection of faculty or content of the presentations.

The 2021 Conference on Retroviruses and Opportunistic Infections has, to date, received grant support commitments from the following ineligible companies:

PLATINUM LEVEL SUPPORT
Gilead Sciences, Inc.
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

BRONZE LEVEL SUPPORT
AbbVie Inc.
Hologic, Inc.
Theratechnologies Inc.

Additional support has been provided by
Cepheid